Covered recipient · General Payments record
RALPH J DUDA
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$93,909.12
141 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $89,172.00 | 64 |
| Travel and Lodging | $3,706.84 | 36 |
| Food and Beverage | $998.01 | 40 |
| Education | $32.27 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $86,917.32 | 122 |
| Amgen Inc. | $6,801.29 | 9 |
| Novo Nordisk Inc | $57.55 | 2 |
| Mallinckrodt Hospital Products Inc. | $37.49 | 2 |
| UCB, Inc. | $33.38 | 2 |
| AbbVie Inc. | $29.52 | 2 |
| Radius Health, Inc. | $19.79 | 1 |
| Janssen Biotech, Inc. | $12.78 | 1 |
Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RALPH J DUDA
NPI 1356436406 · CMS profile ID 151655
Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
SPRINGFIELD, MO
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1356436406?year=2023&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RALPH J DUDA, NPI 1356436406, CMS profile ID 151655. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356436406?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). RALPH J DUDA, NPI 1356436406, CMS profile ID 151655. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356436406?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- RALPH J DUDA, NPI 1356436406, CMS profile ID 151655, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1356436406?year=2023&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
141 matching records · $93,909.12 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–141 of 141.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $1,575.00 | 04/13/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031956693 | CMS |
| Lilly USA, LLC | $1,800.00 | 04/13/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031996623 | CMS |
| Lilly USA, LLC | $11.49 | 04/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032051973 | CMS |
| Lilly USA, LLC | $1,125.00 | 04/12/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031956689 | CMS |
| Lilly USA, LLC | $1,800.00 | 04/12/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032051937 | CMS |
| Mallinckrodt Hospital Products Inc. | $21.65 | 04/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042825713 | CMS |
| Lilly USA, LLC | $21.44 | 04/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032051961 | CMS |
| Lilly USA, LLC | $1,800.00 | 04/04/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032078093 | CMS |
| Lilly USA, LLC | $1,125.00 | 04/04/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032124731 | CMS |
| Lilly USA, LLC | $1,125.00 | 03/31/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031996621 | CMS |
| Lilly USA, LLC | $1,800.00 | 03/31/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032078097 | CMS |
| Lilly USA, LLC | $17.77 | 03/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031956761 | CMS |
| Lilly USA, LLC | $17.65 | 03/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032007145 | CMS |
| UCB, Inc. | $14.40 | 03/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021991613 | CMS |
| Lilly USA, LLC | $1,800.00 | 03/27/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032007135 | CMS |
| Lilly USA, LLC | $675.00 | 03/27/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032101317 | CMS |
| Amgen Inc. | $625.50 | 03/23/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1061168794 | CMS |
| Lilly USA, LLC | $12.22 | 03/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032007139 | CMS |
| Lilly USA, LLC | $28.82 | 03/21/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031956683 | CMS |
| Lilly USA, LLC | $32.00 | 03/21/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032101313 | CMS |
| Janssen Biotech, Inc. | $12.78 | 03/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988225249 | CMS |
| Lilly USA, LLC | $3,600.00 | 03/03/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032124727 | CMS |
| Lilly USA, LLC | $6.25 | 02/23/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032124721 | CMS |
| Lilly USA, LLC | $3.95 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031996651 | CMS |
| Lilly USA, LLC | $35.00 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031996655 | CMS |
| Lilly USA, LLC | $45.00 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031996659 | CMS |
| Lilly USA, LLC | $36.54 | 02/22/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032007169 | CMS |
| Lilly USA, LLC | $25.00 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032007173 | CMS |
| Lilly USA, LLC | $232.00 | 02/22/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032022763 | CMS |
| Lilly USA, LLC | $17.55 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032022769 | CMS |
| Lilly USA, LLC | $59.87 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032022773 | CMS |
| Lilly USA, LLC | $220.04 | 02/22/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032051932 | CMS |
| Lilly USA, LLC | $10.80 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032051983 | CMS |
| Lilly USA, LLC | $136.75 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032078127 | CMS |
| Lilly USA, LLC | $25.00 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032078131 | CMS |
| Lilly USA, LLC | $202.58 | 02/22/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032124717 | CMS |
| Lilly USA, LLC | $9.45 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032124753 | CMS |
| Lilly USA, LLC | $80.00 | 02/17/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032101309 | CMS |
| Lilly USA, LLC | $108.75 | 02/16/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031956681 | CMS |
| UCB, Inc. | $18.98 | 02/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021991617 | CMS |
| Lilly USA, LLC | $61.25 | 02/13/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032078089 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,357,953.33 | 228 |
| PY2024 | Principal investigator | $179,334.40 | 7 |
| PY2023 | Principal investigator | $463,266.44 | 7 |
| PY2022 | Recipient | $44,029.00 | 3 |
| PY2022 | Principal investigator | $400,653.00 | 6 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
228 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension | No dispute reported | 06/30/2026 | 1202533101 |
| Principal investigator 1 | ABBVIE INC. | $189.00 | 12/26/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202532102 |
| Principal investigator 1 | PFIZER INC. | $1,582.00 | 12/19/2025 | Non-covered Recipient Entity Clinvest Headlands LLC | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228744304 |
| Principal investigator 1 | PFIZER INC. | $12,541.11 | 12/17/2025 | Non-covered Recipient Entity Clinvest Headlands LLC | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228733767 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,826.00 | 12/15/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812512 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,000.00 | 12/09/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812508 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $350.00 | 12/09/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812510 |
| Principal investigator 1 | ABBVIE INC. | $420.00 | 12/04/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202527876 |
| Principal investigator 1 | ABBVIE INC. | $4,752.00 | 12/04/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202527878 |
| Principal investigator 1 | ABBVIE INC. | $231.00 | 12/04/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202527880 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724251 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724253 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724255 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724257 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724259 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724261 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,678.50 | 11/25/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184264511 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,722.00 | 11/20/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263655 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $58.80 | 11/20/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263657 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $861.00 | 11/20/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263659 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 11/20/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184263661 |
| Principal investigator 1 | Eli Lilly and Company | $1,020.92 | 11/19/2025 | Non-covered Recipient Entity CLINVEST RESEARCH LLC | RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY4065967 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1187878231 |
| Principal investigator 1 | PFIZER INC. | $6,723.65 | 11/14/2025 | Non-covered Recipient Entity Clinvest Headlands LLC | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228738368 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,055.00 | 11/13/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812506 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,853.20 | 11/13/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184260693 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 11/07/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220807549 |
| Principal investigator 1 | PFIZER INC. | $4,353.81 | 11/07/2025 | Non-covered Recipient Entity Clinvest Headlands LLC | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228739316 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $506.10 | 11/07/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184258961 |
| Principal investigator 1 | ABBVIE INC. | $4,960.00 | 11/05/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202522121 |
| Principal investigator 1 | ABBVIE INC. | $63.00 | 11/04/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202520501 |
| Principal investigator 1 | ABBVIE INC. | $413.00 | 11/04/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202520503 |
| Principal investigator 1 | PFIZER INC. | $8,400.70 | 11/04/2025 | Non-covered Recipient Entity Clinvest Headlands LLC | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228738536 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724239 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724241 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724243 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724245 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724247 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724249 |
| Principal investigator 1 | PFIZER INC. | $3,483.20 | 11/01/2025 | Non-covered Recipient Entity Clinvest Headlands LLC | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228738622 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $39,198.85 | 10/31/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event | No dispute reported | 06/30/2026 | 1185553918 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,919.40 | 10/29/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184253702 |
| Principal investigator 1 | Eli Lilly and Company | $605.01 | 10/28/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | No dispute reported | 06/30/2026 | 1187879517 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.32 | 10/27/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724263 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $179.82 | 10/27/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724265 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $365.00 | 10/27/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724267 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.44 | 10/27/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724269 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.04 | 10/27/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724271 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,722.00 | 10/23/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184252612 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,918.80 | 10/23/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184252614 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $861.00 | 10/23/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184252616 |
| Principal investigator 1 | PFIZER INC. | $8,081.50 | 10/21/2025 | Non-covered Recipient Entity Clinvest Headlands LLC | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228730734 |
| Principal investigator 1 | ABBVIE INC. | $619.19 | 10/16/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202517335 |
| Principal investigator 1 | ABBVIE INC. | $3,168.00 | 10/09/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202516365 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,386.00 | 10/06/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812482 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,540.00 | 10/06/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812484 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,155.00 | 10/06/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812486 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,540.00 | 10/06/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812488 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,309.00 | 10/06/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812490 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,500.00 | 10/06/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812492 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,540.00 | 10/03/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812494 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $500.00 | 10/03/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812496 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,410.00 | 10/03/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812498 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $231.00 | 10/03/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812500 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $154.00 | 10/03/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812502 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $385.00 | 10/03/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812504 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724227 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724229 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724231 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724233 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724235 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724237 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $580.00 | 10/01/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812480 |
| Principal investigator 1 | ABBVIE INC. | $350.00 | 09/23/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202511904 |
| Principal investigator 1 | ABBVIE INC. | $126.00 | 09/23/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202511908 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,422.54 | 09/23/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184241608 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,500.00 | 09/23/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184241634 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,120.00 | 09/23/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184241636 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $58.80 | 09/23/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184241638 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $166.60 | 09/23/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184241640 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $861.00 | 09/23/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184241642 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 09/23/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184241644 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $58.80 | 09/23/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184241646 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16,215.00 | 09/18/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812478 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,200.00 | 09/12/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184236572 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,200.00 | 09/12/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184236574 |
| Principal investigator 1 | ABBVIE INC. | $91.40 | 09/04/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202509436 |
| Principal investigator 1 | ABBVIE INC. | $518.00 | 09/04/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202509438 |
| Principal investigator 1 | ABBVIE INC. | $413.00 | 09/04/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202509440 |
| Principal investigator 1 | ABBVIE INC. | $126.00 | 09/04/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202509442 |
| Principal investigator 1 | ABBVIE INC. | $55.00 | 09/04/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202509566 |
| Principal investigator 1 | ABBVIE INC. | $8,968.00 | 09/04/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202509568 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724193 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724195 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724197 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724199 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724201 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724217 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.79 | 09/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724225 |
| Principal investigator 1 | PFIZER INC. | $8,333.50 | 08/22/2025 | Non-covered Recipient Entity Clinvest Headlands LLC | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228720369 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,032.82 | 08/21/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184229741 |
| Principal investigator 1 | Eli Lilly and Company | $6,521.15 | 08/18/2025 | Non-covered Recipient Entity CLINVEST RESEARCH LLC | RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | No dispute reported | 06/30/2026 | 1187880149 |
| Principal investigator 1 | PFIZER INC. | $2,181.57 | 08/15/2025 | Non-covered Recipient Entity Clinvest Headlands LLC | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228786633 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,835.14 | 08/07/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184226133 |
| Principal investigator 1 | ABBVIE INC. | $9,724.00 | 08/06/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202502981 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $30,987.00 | 08/06/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812476 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,520.00 | 08/05/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812474 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724181 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724183 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724185 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724187 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724189 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724191 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724215 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,540.00 | 07/30/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812464 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,540.00 | 07/30/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812466 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,540.00 | 07/30/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812468 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,540.00 | 07/30/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812470 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,540.00 | 07/30/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812472 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 07/28/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724219 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $110.55 | 07/28/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724221 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.70 | 07/28/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724223 |
| Principal investigator 1 | ABBVIE INC. | $1,134.61 | 07/24/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202499668 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 07/22/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202499122 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,079.42 | 07/22/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184217761 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,950.00 | 07/19/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812462 |
| Principal investigator 1 | PFIZER INC. | $13,876.60 | 07/18/2025 | Non-covered Recipient Entity Clinvest Headlands LLC | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228774182 |
| Principal investigator 1 | ABBVIE INC. | $63.00 | 07/17/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202498760 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $435.00 | 07/16/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812448 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $231.00 | 07/16/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812450 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $750.00 | 07/16/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812452 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $290.00 | 07/16/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812454 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $231.00 | 07/16/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812456 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $262.00 | 07/16/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812458 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,070.00 | 07/16/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812460 |
| Principal investigator 1 | ABBVIE INC. | $63.00 | 07/15/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202498296 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,739.22 | 07/10/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184214364 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $294.00 | 07/09/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812444 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,520.00 | 07/09/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812446 |
| Principal investigator 1 | ABBVIE INC. | $3,168.00 | 07/02/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202496439 |
| Principal investigator 1 | PFIZER INC. | $5,000.00 | 07/02/2025 | Non-covered Recipient Entity Clinvest Headlands LLC | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228763355 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724203 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724205 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724207 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724209 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724211 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724213 |
| Principal investigator 1 | Eli Lilly and Company | $156,558.64 | 07/01/2025 | Non-covered Recipient Entity CLINVEST RESEARCH LLC | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND LONG-TERM SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-2) | No dispute reported | 06/30/2026 | 1187880145 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $36,792.00 | 06/26/2025 | Non-covered Recipient Entity Clinvest Headlands, LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220812442 |
| Principal investigator 1 | ABBVIE INC. | $63.00 | 06/25/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202492835 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $81.62 | 06/24/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724179 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $755.72 | 06/24/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184210642 |
| Principal investigator 1 | ABBVIE INC. | $189.00 | 06/18/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202492103 |
| Principal investigator 1 | ABBVIE INC. | $1,680.00 | 06/18/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202492105 |
| Principal investigator 1 | ABBVIE INC. | $1,200.00 | 06/18/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202492117 |
| Principal investigator 1 | ABBVIE INC. | $210.00 | 06/17/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202491717 |
| Principal investigator 1 | Eli Lilly and Company | $4,674.00 | 06/16/2025 | Non-covered Recipient Entity CLINVEST RESEARCH LLC | A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) | No dispute reported | 06/30/2026 | 1187878229 |
| Principal investigator 1 | ABBVIE INC. | $126.00 | 06/12/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202491049 |
| Principal investigator 1 | ABBVIE INC. | $231.00 | 06/12/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202491089 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,114.42 | 06/12/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184206241 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,722.00 | 06/12/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184206243 |
| Principal investigator 1 | ABBVIE INC. | $7,384.00 | 06/11/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202490837 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,114.42 | 06/05/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184204175 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.88 | 06/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724163 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 06/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724165 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724167 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724169 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724171 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724173 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724175 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Clinvest Research | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220724177 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,881.62 | 05/28/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184198897 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $755.72 | 05/22/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184197655 |
| Principal investigator 1 | ABBVIE INC. | $4,500.00 | 05/15/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202485211 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,037.64 | 05/15/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184194661 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $499.80 | 05/15/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184194667 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $58.80 | 05/15/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184194677 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 05/15/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184194679 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 05/15/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184194687 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 05/15/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184194703 |
| Principal investigator 1 | ABBVIE INC. | $189.00 | 05/14/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202484805 |
| Principal investigator 1 | Eli Lilly and Company | $6,665.85 | 05/12/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187877937 |
| Principal investigator 1 | Eli Lilly and Company | $7,544.00 | 05/12/2025 | Non-covered Recipient Entity CLINVEST RESEARCH LLC | A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 1 DIABETES TREATED WITH MULTIPLE DAILY INJECTION THERAPY | No dispute reported | 06/30/2026 | 1187878051 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $755.72 | 05/08/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184193759 |
| Principal investigator 1 | ABBVIE INC. | $8,884.00 | 05/07/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202482467 |
| Principal investigator 1 | ABBVIE INC. | $126.00 | 04/30/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202480567 |
| Principal investigator 1 | ABBVIE INC. | $63.00 | 04/30/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202480637 |
| Principal investigator 1 | Eli Lilly and Company | $270.00 | 04/30/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187877189 |
| Principal investigator 1 | ABBVIE INC. | $224.00 | 04/29/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202479855 |
| Principal investigator 1 | ABBVIE INC. | $756.00 | 04/24/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202479095 |
| Principal investigator 1 | ABBVIE INC. | $252.00 | 04/24/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202479099 |
| Principal investigator 1 | ABBVIE INC. | $504.00 | 04/24/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202479103 |
| Principal investigator 1 | ABBVIE INC. | $252.00 | 04/24/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202479370 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $166.60 | 04/23/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184189105 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $58.80 | 04/23/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184189107 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $166.60 | 04/23/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184189109 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $117.60 | 04/23/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184189111 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,860.00 | 04/23/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184189113 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $166.60 | 04/23/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184189115 |
| Principal investigator 1 | Eli Lilly and Company | $248.77 | 04/21/2025 | Non-covered Recipient Entity CLINVEST RESEARCH LLC | A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187877585 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,367.44 | 04/15/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184183434 |
| Principal investigator 1 | Eli Lilly and Company | $1,182.00 | 04/08/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187878223 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,628.22 | 04/08/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184182060 |
| Principal investigator 1 | ABBVIE INC. | $5,704.00 | 04/03/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202474149 |
| Principal investigator 1 | Eli Lilly and Company | $84,972.00 | 04/01/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187879275 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,739.22 | 04/01/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY | No dispute reported | 06/30/2026 | 1184180830 |
| Principal investigator 1 | Eli Lilly and Company | $132,556.89 | 03/24/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND CHRONIC LOW BACK PAIN (TRIUMPH-7) | No dispute reported | 06/30/2026 | 1187877579 |
| Principal investigator 1 | Eli Lilly and Company | $1,084.96 | 03/10/2025 | Non-covered Recipient Entity CLINVEST RESEARCH LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187882258 |
| Principal investigator 1 | ABBVIE INC. | $7,652.00 | 03/07/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202460110 |
| Principal investigator 1 | Eli Lilly and Company | $225.00 | 03/06/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187879273 |
| Principal investigator 1 | Eli Lilly and Company | $4.54 | 03/03/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187879515 |
| Principal investigator 1 | Eli Lilly and Company | $870.91 | 02/25/2025 | Non-covered Recipient Entity CLINVEST RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187877583 |
| Principal investigator 1 | Eli Lilly and Company | $32,393.00 | 02/18/2025 | Non-covered Recipient Entity CLINVEST RESEARCH LLC | A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, TWO-ARM, PHASE 4 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED WITH INTENSIFIED CONVENTIONAL CARE IN ADULTS WHEN INITIATING TREATMENT EARLY IN THE COURSE OF TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187878295 |
| Principal investigator 1 | ABBVIE INC. | $4,120.00 | 02/06/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202448023 |
| Principal investigator 1 | Eli Lilly Export S.A. Puerto Rico Branch | $506.00 | 01/31/2025 | Non-covered Recipient Entity CLINVEST RESEARCH LLC | A STUDY OF ORFORGLIPRON (LY3502970) IN PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH INSULIN GLARGINE, WITH OR WITHOUT METFORMIN AND/?OR SGLT-2 INHIBITOR (ACHIEVE-5) | No dispute reported | 06/30/2026 | 1187880097 |
| Principal investigator 1 | Eli Lilly and Company | $572.24 | 01/31/2025 | Non-covered Recipient Entity CLINVEST RESEARCH LLC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187879521 |
| Principal investigator 1 | Eli Lilly and Company | $4,386.15 | 01/31/2025 | Non-covered Recipient Entity CLINVEST RESEARCH LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187882256 |
| Principal investigator 1 | Eli Lilly and Company | $52.99 | 01/27/2025 | Non-covered Recipient Entity SCOTT HEALTH SERVICES LLC | A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | No dispute reported | 06/30/2026 | 1187889398 |
| Principal investigator 1 | Eli Lilly and Company | $3,203.18 | 01/22/2025 | Non-covered Recipient Entity CLINVEST RESEARCH LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187879525 |
| Principal investigator 1 | Eli Lilly and Company | $36,949.16 | 01/21/2025 | Non-covered Recipient Entity CLINVEST RESEARCH LLC | A STUDY OF ORFORGLIPRON (LY3502970) IN PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH INSULIN GLARGINE, WITH OR WITHOUT METFORMIN AND/?OR SGLT-2 INHIBITOR (ACHIEVE-5) | No dispute reported | 06/30/2026 | 1187876587 |
| Principal investigator 1 | ABBVIE INC. | $9,999.96 | 01/15/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202438685 |
| Principal investigator 1 | Eli Lilly and Company | $19,015.00 | 01/13/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | No dispute reported | 06/30/2026 | 1187876585 |
| Principal investigator 1 | Eli Lilly and Company | $115,539.00 | 01/13/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187877935 |
| Principal investigator 1 | Eli Lilly and Company | $44,324.52 | 01/13/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187879511 |
| Principal investigator 1 | Eli Lilly and Company | $1,415.72 | 01/09/2025 | Non-covered Recipient Entity CLINVEST RESEARCH LLC | RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | No dispute reported | 06/30/2026 | 1187876589 |
| Principal investigator 1 | Eli Lilly and Company | $8,834.99 | 01/09/2025 | Non-covered Recipient Entity CLINVEST RESEARCH LLC | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187878227 |
| Principal investigator 1 | Eli Lilly and Company | $131,763.85 | 01/07/2025 | Non-covered Recipient Entity CLINVEST RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187878297 |
| Principal investigator 1 | Eli Lilly and Company | $113,349.00 | 01/07/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187879271 |
| Principal investigator 1 | ABBVIE INC. | $3,168.00 | 01/02/2025 | Non-covered Recipient Entity CLINVEST HEADLANDS LLC | M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202434481 |